Leuprorelin - Chong Kun Dang

Alternative Names: CKD-841; CKD-841 A-1; CKD-841 D

Latest Information Update: 04 Jan 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chong Kun Dang
Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
Mechanism of Action Gonadotropin releasing hormone stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

04 Jan 2023 Leuprorelin is still in phase I development for Cancer in South Korea (SC) (CHONG KUN DANG pipeline, January 2023)
28 Feb 2022 No recent reports of development identified for phase-I development in Cancer in South Korea (SC, Injection)
12 Apr 2021 Chong Kun Dang Pharmaceutical plans a phase I trial (In volunteers) in South Korea (SC) (NCT04840745)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com